| PATIENTS AND ME THODS

| Patients
Patients were recruited from the Queen Silvia Children's Hospital after informed consent from the children and their parents. The mean follow-up time was 1030 days. The local research ethics committee of Göteborg University, Sweden, approved this study (no. Ö374-01). The study group, at baseline, comprised 13 patients with CKD, 9 males and 4 females, median age 9.3 years (3.4-15.0 years) at inclusion. GFR was calculated according to the formula by Schwartz et al. 20 Underlying nephropathy types were malformation (n = 8), Laurence-Moon-Biedl syndrome (n = 1), and acquired diseases (n = 4). Conservative treatment was given when indicated with sodium bicarbonate, calcium carbonate, and alfacalcidol, but no patients received aluminum-containing phosphate binders before the transplantation. Antihypertensive treatment was given when indicated. Eleven patients received their first transplant and two patients their second transplant. Six patients received treatment with recombinant human GH before transplantation. Five patients had early rejections and received intravenous methyl prednisolone for 3-4 days. Our immunosuppression protocol included daily steroids for 3 months (Table 1) , thereafter on alternate days for at least another 3 months, calcineurin inhibitors and mycophenolate mofetil.
| Assessment of bone mass and bone age
BMD and BMC for total body were assessed by the Lunar DPX IQ (pencil beam) (GE Lunar Corp., Madison, WI, USA). DXA measures bone in 2 dimensions, and this areal BMD, and not true volumetric BMD, is referred to BMD (g/cm 2 ) in this study. The calculated Z-scores were age-and gender-specific. Lean body mass and fat mass were also measured. In the DXL Calscan technique, BMD is measured using DXA in combination with laser measurements of the total heel thickness. This technology reduces the uncertainty related to the variable composition of soft tissue in adults. 21 For calcaneal BMD, the DXL Calscan (Demetech AB, Täby, Sweden) has been used for diagnosis of osteoporosis in adults and is in conjunction with measurements by axial DXA technology. 22, 23 The original DXL Calscan for adults has been modified for use in pediatric patients and has been shown to measure BMD with high accuracy. 24 The DXL Calscan pediatric version includes a function, which makes it possible to measure the calcaneal height. This height, together with the BMD value, provides an opportunity to calculate the volumetric bone mineral apparent density, which could be valuable when measuring bones of different sizes as, for example, for growing individuals. 24 The left foot of each child was measured. Regular hand X-ray was used to assess signs of rickets and to assess bone age by the TW2 and GP methods at the Department of Radiology, The Queen Silvia Children's Hospital, Göteborg, Sweden.
| Biochemical determinations
A detailed description of the biochemical methods applied has been reported elsewhere. 25 Serum intact PINP was determined by RIA (Orion Diagnostica, Oulunsalo, Finland). Serum total ALP was measured by a kinetic assay with 1.0 M diethanolamine buffer (pH 9.8), for weight SDS (P = .0002), height SDS (P = .0012), and BMI SDS (P = .013) after 3 years. According to the age-and gender-adjusted F I G U R E 1 Auxological data for weight, height, and BMI SDS for each patient over 3 y Swedish classification of overweight, 26 6 and 4 patients were overweight after 1 year and 3 years, respectively, after kidney transplantation. The fat mass percentage increased after transplantation (from median 12.9% to 27.4%), P < .01, and total lean mass was unchanged after 3 months, but increased after 1 year and 3 years (from median 23.1 kg (84.3%) at baseline to 29.3 kg (70.4%) after 3 years), P < .01.
| Growth and body composition
| Bone mass and bone age
Bone mass data, that is, BMC and BMD, are presented in Table 2 for total body and calcaneus measurements. Total BMC increased at all time points in comparison with the initial values at study start, P < .001 (Table 2 ; Figure 2 ). No change was observed for total BMD over the study period, which is reflected by the decrease in total body BMD (TBBMD) Z-score over the study period. None of the included patients had a TBBMD Z-score below −2.0 during the study period. Calcaneal BMC and BMD did not change at any time point.
At start, we observed a delayed median bone age by 0.9 year (TW2) and 0.8 year (GP) in comparison with the chronological age.
Bone age was still delayed after 3 years post-transplantation, that is, 1.5 years (TW2) and 0.9 year (GP). Two patients sustained clavicle fractures during the study period, but no other fractures were reported.
| Biochemical markers of bone and mineral metabolism
Median PTH was 254 ng/L prior transplantation, but decreased rapidly to 81 ng/L after 3 months (P < .01) and remained stable throughout the first year after transplantation. An additional decrease was observed between 3 months and 3 years, median 69 ng/L (P < .05).
A similar pattern of decrease was found for serum phosphate after 3 months and 3 years (P < .05), as well as for magnesium after 3 months and 3 years (P < .01). No effect was found for serum 25(OH)D after 3 months and 1 year, but an increase was found after 3 years (P < .05). The levels of 1,25(OH) 2 D increased after the first year and 3 years (P < .002) in comparison with baseline. Serum total calcium and ionized calcium remained unchanged throughout the post-transplantation period. Median serum OPG decreased from 4.1 pmol/L at baseline to 2.8 pmol/L 3 months post-transplantation, P < .01, but returned to baseline levels after 1 year and 3 years.
Individual data (percentage change from baseline) for the bone resorption markers CTX and TRACP5b, and bone formation markers intact PINP, total ALP, and osteocalcin are shown in Figure 3 . Serum CTX decreased significantly after 3 months, 1 year, and 3 years in comparison with baseline values, P < .01, which is in line with the increased GFR levels at each time point after kidney transplantation (Table 1) . Serum TRACP5b decreased initially after 3 months (P < .05) and remained stable throughout the study period. PINP decreased after 3 months (P < .05), but returned to baseline levels 1 year and 3 years post-transplantation. Total ALP was unchanged until 3 months, but increased between 3 months and 1 year posttransplantation (P < .01). Serum osteocalcin decreased significantly during the first 3 months (P < .0005), but increased thereafter during the study period (P < .002) (Figure 3 ). Further statistical assessments of subgroups based on gender, age, growth patterns, CKD stages, or estimated cumulative steroid dosages were not justified due to the small study group. For all measurements, n = 13. Values are given as mean ± SD, median, with minimum and maximum values in parentheses. *P < .05, * * P < .01, * ** P < .001, Wilcoxon signed rank test.
| D ISCUSS I ON
transplantation had a favorable impact on growth outcomes. Bone resorption markers decreased initially and remained stable throughout the study period, whereas the bone formation markers increased successively.
Growth failure is a frequent complication of CKD, and GH treatment is therefore commonly used to enhance growth in children with CKD. 12 Kidney transplantation is, however, the best treatment for growth-deficient children with CKD, which results in a sustained increase in height and restoration of body proportions in most patients. 27 We observed a similar increase in height in the current study; that is, median height SDS increased from −1.7 to −1.1 after 3 years, and median BMI SDS increased from −0.1 to 0.6 after 3 years, which shows that transplantation had a favorable impact on growth outcomes. Zivicnjak et al 28 reported, from a 7-year cohort study, a specific age-dependent growth pattern in pediatric patients with CKD. The most severe growth failure was observed during early childhood, followed by an accelerated growth during prepuberty, slowing-down of growth at puberty, and thereafter a late catch-up growth until early adulthood. It has been suggested that growth failure in CKD is caused by a relative GH insensitivity and functional insulin-like growth factor-I deficiency. 29 Growth restriction is very common in children with CKD, and the assessment of skeletal maturity (bone age) is an important prerequisite to evaluating the individual growth delay and growth potential. 30 Median radiological bone age was still delayed after 3 years in the current study.
Bone and fat mass are linked; thus, changes in body composition after kidney transplantation affect growth and skeletal development in children. The fat mass percentage increased after transplantation in the current study, at all time points, whereas lean mass increased after 1 year and 3 years. Treatment with glucocorticoids, after kidney transplantation, causes an initial increase in fat mass which later on is reduced with a subsequent increase in lean mass as patients recover and probably increase their mobility and degree of physical activity. The increase in lean mass is favorable for bone acquisition, as muscle mass affects bone mass positively. 31 Our findings coincide with a Hungarian pediatric study where the prevalence of overweight/obese patients was low at transplantation and rose subsequently. 32 In another Scandinavian cohort, one-third of the pediatric patients were overweight/obese after kidney transplantation, 33 which was not found in the current study as most patients had a median BMI SDS of 0.6.
A 2015 meta-analysis indicates that BMD is low in patients with CKD stage 3-5 with fractures, which suggests that BMD measurements may be clinically useful in assessing fracture risk in CKD. 34 DXA has been recommended to follow up kidney transplant recipients. 14, 35, 36 Recent studies measuring BMD by DXA have demonstrated that low BMD is common in pediatric kidney transplant recipients. 13, 37, 38 An increase in total BMC, at all time points, was found, which corroborates the significant increase in height SDS and thereby positive net gain in mineral acquisition. None of the included patients had a TBBMD Z-score below −2.0 during the study period, some insight into trabecular and cortical compartments following transplantation. 40 The interpretation of biochemical markers of bone and mineral metabolism is complex in growing children and adolescents due to the multifaceted mechanism of longitudinal growth. 41 Another aspect to take into account, regarding interpretation of bone formation markers, is the three major events during osteogenesis, that is, proliferation with collagen synthesis, extracellular matrix maturation, and mineralization. In vitro studies have shown a sequential expression of genes during osteoblast differentiation;
that is, messenger RNA of type I collagen is expressed first, followed by ALP, and finally osteocalcin. 42 In vivo studies have shown F I G U R E 3 Individual data, given as percentage change after kidney transplantation, over 3 years for biochemical markers of bone turnover a corresponding time course for the three different stages following the circulating levels of bone formation markers PINP, ALP, and osteocalcin during anabolic GH treatment. 41 Although that kidney transplantation favors the acquisition of bone mineral, as shown by the increase in total body BMC, it cannot be regarded as a definite anabolic treatment in the same fashion as GH. The lack of uniformity for ALP, shown in Figure 3 The current study has a number of strengths, including the prospective design, broad approach with the combination of growth evaluation, body composition, bone mass measurements, and markers of bone and mineral metabolism. The low number of patients is a limitation of the study that warrants consideration when interpreting the data. On a positive note, the current study comprises only data from kidney transplant recipients; thus, it is not a blend of solid-organ transplant patients which often is reported in the literature. We lacked matching controls in this study, but there is currently no consensus on the optimal approach for control-matching BMD and BMC for factors such as body composition, pubertal stage, and skeletal maturity.
Bone health in children and adolescents has emerged as a significant area of clinical interest, and expanding area of research, as many chronic diseases affect the skeleton with long-term consequences. Worldwide, more and more children benefit from kidney transplantation, and prospective studies are therefore warranted.
This longitudinal prospective study demonstrates that height SDS and BMI SDS increased, along with the increased markers of bone formation that reveal positive bone acquisition after kidney transplantation, which was reflected by the significant increase in total body BMC.
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